**Background**
Endometriosis, uterine fibroids, and adenomyosis are common gynecological disorders characterized by the growth of endometrial-like tissue or benign tumors, often driven by the hypothalamic-pituitary-gonadal (HPG) axis. The gonadotropin-releasing hormone (GnRH) receptor plays a pivotal role in regulating the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which in turn control the production of sex steroids. By antagonizing the GnRH receptor, it is possible to suppress the HPG axis and reduce the hormonal stimulation that fuels these estrogen-dependent conditions. Consequently, developing potent, non-peptide antagonists that can be administered orally is a significant goal for improving patient outcomes and research models. In this context, we will introduce a potent GnRH antagonist – Linzagolix.
**Definition**
Linzagolix (also known as KLH-2109 or OBE-2109) is a potent, non-peptide, and orally active GnRH antagonist. According to the Linzagolix description, this compound is designed to suppress the HPG axis to treat hormone-dependent gynecological and urological conditions.
**In Vivo Studies**
The Linzagolix biological activity has been demonstrated across several animal models to validate its efficacy in suppressing gonadal function. In vivo studies using an endometriosis model rat showed that administration of Linzagolix at a dosage of 50 mg/kg resulted in a significant reduction in cyst volume. Furthermore, research involving male rats and dogs, including those with benign prostatic hyperplasia (BPH) models, indicated that Linzagolix reduces serum luteinizing hormone and testosterone levels. These findings suggest that the compound effectively inhibits the release of gonadotropins, thereby lowering the systemic levels of sex steroids. For researchers seeking detailed Linzagolix technical information regarding its molecular weight of 508.42 and its specific chemical structure, the compound provides a robust tool for studying the suppression of the HPG axis. In conclusion, Linzagolix is a potent, orally active non-peptide GnRH antagonist that holds promise for the research of endometriosis, uterine fibroids, and adenomyosis.
Keywords
Linzagolix, 935283-04-8, KLH-2109, OBE-2109, KLH2109, KLH 2109, OBE2109, OBE 2109, GnRH Receptor, Gonadotropin releasing hormone receptor, GNRHR, uterine fibroids, endometriosis, adenomyosis
References
[1] Susan Dababou, et al. Linzagolix: a new GnRH-antagonist under investigation for the treatment of endometriosis and uterine myomas. Expert Opin Investig Drugs. 2021 Sep;30(9):903-911.
[2] Motohiro Tezuka, et al. Suppressive effects of linzagolix, a novel non-peptide antagonist of gonadotropin-releasing hormone receptors, in experimental endometriosis model rats. Clin Exp Pharmacol Physiol. 2023 Jul;50(7):610-617.
[3] Motohiro Tezuka, et al. Suppression of hypothalamic-pituitary-gonadal function by linzagolix in benign prostatic hyperplasia and polycystic ovary syndrome animal models. Clin Exp Pharmacol Physiol. 2023 Nov;50(11):914-923.